OnCo
companiesCompany

Arvinas

PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026.

Vepdegestrant (ER, with Pfizer), ARV-393 (BCL6), ARV-102 (LRRK2, neurology); founded on Craig Crews' PROTAC technology.

Headquarters
New Haven, CT, US
Type
biotech · ARVN

Products

1top
ApprovedPROTAC oestrogen receptor degrader
Vepdegestrant · Veppanu

Vepdegestrant is the first PROTAC ever approved (2026): a pill that tags the oestrogen receptor for destruction, for breast cancers with ESR1 mutations.

Connected

7top

cancers

1
HR-positive / HER2-negative breast cancer

fronts

1
Targeted Therapy

technologies

1
PROTACs & molecular glues (targeted protein degradation)

drugs

1
ApprovedPROTAC oestrogen receptor degrader
Vepdegestrant · Veppanu

ideas

2
An open degrader consortium against every undruggable driver transcription factorDestroy the truncated androgen receptor that hormone drugs cannot touch

bottlenecks

1
The undruggable drivers